Brad A. Hauser is the new president and chief executive officer of Soliton. Hauser most recently served as vice president of research and development and general manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017 acquisition of ZELTIQ Aesthetics. Prior to Allergan's acquisition of ZELTIQ, Hauser held a number of positions at Zeltiq, including senioir vice president of research and development and vice president of product and clinical strategy, and also worked with Solta Medical and Medicis.
"We are extremely excited to welcome Brad Hauser as CEO. We believe this is a monumental and pivotal appointment for the future of Soliton given Brad's well-established reputation in the aesthetics industry. His deep expertise in aesthetics and his leadership in the commercialization of CoolSculpting serve as a powerful endorsement for the potential of the Soliton RAP device. As a long-standing member of our board, Brad has provided excellent guidance and insight for the Soliton pipeline. We are very encouraged by the commercialization experience and skill set he brings to the CEO role," said Walter Klemp, Soliton co-founder and executive chairman.
"I am thrilled to be joining the Soliton team. We are at a very exciting point in the organization's life cycle and are gearing up to launch an innovative technology that has the potential to change how the industry addresses two real patient needs: faster, effective tattoo removal and a completely non-invasive solution for cellulite reduction, which is currently pending FDA clearance," said Mr. Hauser.
Soliton co-founder and chief scientific officer Christopher Capelli, MD, will advance to vice chairman of the Company's Board of Directors and continue to lead Soliton's research and development efforts.
